This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival
by Zacks Equity Research
Jazz (JAZZ) reports data from a mid-stage study on its investigational bispecific antibody targeting HER2-expressing mGEA. The treatment achieved an overall survival rate of 84% in 18 months.
bluebird (BLUE) Stock Dives on Public Offering of Common Stock
by Zacks Equity Research
bluebird (BLUE) to issue secondary shares, diluting its current shareholder base. The company plans to raise $120 million in gross proceeds from this issue.
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Allogene Therapeutics (ALLO) have performed compared to their sector so far this year.
Moderna (MRNA) Up on Upbeat Data From Phase III Study on RSV Jab
by Zacks Equity Research
Data from a late-stage study showed that Moderna's (MRNA) RSV vaccine was 83.7% effective at preventing at least two symptoms in adults aged 60 and older.
Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why
by Zacks Equity Research
Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies
by Zacks Equity Research
Aprea Therapeutics (APRE) advances its novel macrocyclic ATR inhibitor into early-stage clinical studies for treating advanced solid tumors.
Amarin's (AMRN) Q4 Preliminary Revenues Top Expectations
by Zacks Equity Research
Amarin Corporation (AMRN) expects to generate total revenues in the range of $88-$90 million in fourth-quarter 2022. Share price rises following the announcement.
Arvinas, Inc. (ARVN) Soars 10.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Arvinas, Inc. (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Emergent (EBS) to Start Restructuring Plan, Lays Off 5% Workforce
by Zacks Equity Research
Once this restructuring activity is completed, Emergent BioSolutions (EBS) expects to result in annualized savings of over $60 million. It also slightly raised its total revenue guidance for 2022.
Moderna (MRNA) Reports 2023 Business View & Pipeline Updates
by Zacks Equity Research
Moderna (MRNA) expects to record a minimum of $5 billion in revenues from COVID vaccine sales in 2023. It also expects to incur around $4.5 billion as R&D expenses in 2023.
FDA Accepts AstraZeneca (AZN), Sanofi's RSV Antibody BLA
by Zacks Equity Research
The FDA's decision on AstraZeneca (AZN)/Sanofi's (SNY) regulatory filing, seeking approval for using their RSV antibody in all infants, is expected in third-quarter 2023.
GSK Signs Deal to Develop Antibodies for Treating Cancer
by Zacks Equity Research
GSK (GSK) partners with WuXi Biologics to develop bi- & multi-specific T-cell engaging antibodies. GSK will have an exclusive license to develop and commercialize these candidates.
Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout
by Zacks Equity Research
Moderna (MRNA) inks an agreement to acquire OriCiro for $85 million. The acquisition is expected to expand and boost Moderna's mRNA manufacturing capabilities.
BioMarin's (BMRN) Voxzogo Expanded Label Filing Accepted by EMA
by Zacks Equity Research
The EMA validates BioMarin's (BMRN) label expansion filing for Voxzogo to treat children under two years with achondroplasia. BMRN submits a filing for using Voxzogo in children under five years.
Down -41.38% in 4 Weeks, Here's Why Allogene Therapeutics (ALLO) Looks Ripe for a Turnaround
by Zacks Equity Research
Allogene Therapeutics (ALLO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Wall Street Analysts Think Allogene Therapeutics (ALLO) Could Surge 159%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Allogene Therapeutics (ALLO) points to a 158.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Allogene Therapeutics (ALLO) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts Believe Allogene Therapeutics (ALLO) Could Rally 137%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 137.5% upside potential for Allogene Therapeutics (ALLO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Allogene (ALLO) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the mark. ALLO will host an R&D showcase later this month and discuss updated clinical data on its pipeline candidates.
Allogene Therapeutics (ALLO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 6.45% and 45.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy
by Zacks Equity Research
Allogene (ALLO) starts the pivotal phase II ALPHA2 study evaluating its allogeneic CAR T therapy, ALLO-501A in patients with relapsed/refractory large B-cell lymphoma.
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 9.09% and 12.33%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO) Down 10.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allogene (ALLO) Q1 Earnings Beat, Pipeline Progressing Well
by Zacks Equity Research
Allogene's (ALLO) second-quarter earnings beat estimates. ALLO is on track to initiate a pivotal phase II study on ALLO-501A in large B cell lymphoma in the coming weeks.